The Power Behind Precision Antibody Discovery

Geneious Biologics is a next-generation cloud software solution, purpose-built for commercial therapeutic antibody discovery and screening. Delivered through a modern, user-friendly web interface, Geneious Biologics leverages the power of Big Data to help deliver the life-saving drugs of the future.

NGS is Accelerating Therapeutic Antibody Discovery – What Lies Beyond?

This eBook explains why a cloud-based bioinformatics platform is needed to extract maximum value from NGS data.

Apply the Power of Geneious Biologics to Your Antibody NGS Data

Analyze

  • Analyze millions of NGS raw antibody sequences in seconds
  • Preview, annotate, and compare NGS sequences, with no manual intervention

Visualize

  • Compare NGS datasets, plot germline diversity, and region frequency
  • Inspect individual sequences in large datasets using Geneious’ intuitive sequence viewer

Discover

  • Spot high-level trends in large scale antibody NGS datasets
  • Accelerate precision antibody discovery

“…Geneious Biologics solutions have significantly simplified our analyses of these vast (NGS) datasets.”

– Dr. Guy Herman, CSO Isogenica Ltd., UK

Realize Real Business Benefits with Geneious Biologics

Scalability

Scale up quickly and efficiently, with additional capacity delivered on demand

Accuracy

Pick winners and eliminate failures with real-time data consolidation and advanced analytics

Competitive Advantage

Innovate faster and beat competitors to the market with large scale computational analysis in the cloud

Collaboration

The right information at the right time, with a unified, central database, searchable across the organization 

Integration

Access data wherever it resides by integrating multiple systems with sequence data

Configuration

Work with and enhance existing systems with an advanced API and a highly configurable system

“Often, you have to shoehorn a software solution into your process; the adaptability of Geneious Biologics was something we liked a lot. Once we knew what we could do with Geneious Biologics, there was no other viable option.”

Liuhong Chen, Ph.D. Discovery Biology Team Leader at Bicycle Therapeutics